Multiple Myeloma

A real-world study found patients with relapsed/refractory multiple myeloma who were triple-class exposed had higher healthcare costs and unmet treatment needs.

Key takeaways from the CARTITUDE-1 study and the KarMMA study evaluating CAR T-cell therapies for relapsed/refractory multiple myeloma.

An overview of BCMA-targeting bispecific agents in development for multiple myeloma, including talquetamab and teclistamab.

A panel of doctors discuss the available treatment options for early and late relapsed multiple myeloma, including approved novel BCMA-targeting agents.

A look at the patient outcomes with daratumumab use in the frontline vs second-line setting in patients with transplant-ineligible multiple myeloma, and the pros and cons of subcutaneous vs intravenous daratumumab.

Patients with multiple myeloma and high-risk cytogenetics may benefit from treatment with high-dose therapy consolidation compared with delaying this approach.

Experts share their excitement for upcoming PFS trial data to be presented on the combination of ixazomib, pomalidomide, and dexamethasone in multiple myeloma.

Expert perspectives on the triplet combination of ixazomib, pomalidomide, and dexamethasone in multiple myeloma presented at the 2021 ASH [American Society of Hematology] Annual Meeting.

Continuing their discussion on the management of multiple myeloma, experts Paul Richardson, MD, and Cristina Gasparetto, MD, consider the value of minimal residual disease as a marker.

Investigators spoke to the disparities that are present in multiple myeloma and possible causes such as socioeconomic factors.

Suzanne Fanning, DO, and Joshua Richter, MD, discuss clinical implications of a real-world study of ixazomib, lenalidomide, and dexamethasone compared with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.

A review of the available first-line treatment options for transplant-ineligible multiple myeloma, as well as the design and findings of the MAIA study.

Experts explain how to determine treatment duration and a successful response to induction therapy for transplant-eligible multiple myeloma.

Insight on the ASH 2021 update highlighting response rates and discontinuation in patients who received in-class transition from bortezomib to ixazomib for multiple myeloma.

Reflections on the patient-reported adherence and outcome data with IRd (ixazomib, lenalidomide, dexamethasone) therapy after an in-class transition from bortezomib to ixazomib for patients with multiple myeloma.

A real-world study using a voluntary questionnaire found an association between increased pain severity and decreased health-related quality of life for patients with multiple myeloma.

Experts Paul Richardson, MD, and Cristina Gasparetto, MD, discuss trial data analyzing the in-class transition from bortezomib to ixazomib for patients with multiple myeloma.

Expert perspectives on data from the TOURMALINE-MM1 trial, which tested ixazomib therapy in patients with relapsed/refractory multiple myeloma.

Experts provide their recommendations for navigating a large and continuously growing treatment landscape, selecting between regimens, and monitoring patients with transplant-ineligible multiple myeloma.

A discussion on choosing between triplet or quadruplet induction therapy for transplant-eligible newly diagnosed multiple myeloma.

An overview of the triplet and quadruplet induction treatment regimens available for patients with transplant-eligible multiple myeloma and key clinical trials studying daratumumab and isatuximab presented at ASH 2021, with emphasis on the GRIFFIN, MASTER and GMMG-HD7 studies.

Survival among patients with multiple myeloma appears to be influenced by factors such as socioeconomic status and treatment facility type.

Shared insight on how real-world experience and data with proteasome inhibitors in multiple myeloma compare to what was seen in clinical trials.

A broad look at the historical use of proteasome inhibitor therapy in patients with multiple myeloma centered on 3 agents: bortezomib, carfilzomib, and ixazomib.

The FDA granted fast track designation to the BCMA-targeting Tri-specific T-cell Activating Construct, HPN217, for patients with relapsed or refractory multiple myeloma who received at least 4 lines of prior therapy.

Thomas Martin, MD, spoke about how the approval of ciltacabtagene autoleucel for patients with relapsed/refractory multiple myeloma may change the standard of care in this setting.

In an interview with CancerNetwork®, Thomas G. Martin spoke about how the approval of ciltacabtagene autoleucel will likely dramatically impact the standard of care for patients with relapsed/refractory multiple myeloma.

Thomas Martin, MD, spoke about how to increase response durability with ciltacabtagene autoleucel for patients with heavily pretreated multiple myeloma.

Elderly patients with multiple myeloma who were treated with first-line bortezomib had a higher risk of falls vs age-matched controls.

Thomas Martin, MD, spoke about which patient population with relapsed/refractory multiple myeloma would benefit most from treatment with ciltacabtagene autoleucel.